Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)
Table 3
Clinical characteristics and treatment outcomes of ONJ cases.
%
Bone involved
Mandible only
122
61.0
Maxilla only
57
28.5
Maxilla and mandible
21
10.5
Possible risk factors
Smoking habit
Active smokers
35
17.5
Past smokers
15
7.5
Never smokers
146
73.0
Unknown/unavailable
4
2.0
Steroids
None
64
32.0
Massive
91
45.5
Occasionally
40
20.0
Unknown
5
2.5
Diabetes mellitus
28
14.0
Chemotherapy
None
35
17.5
Prior
32
16.0
Concomitant
84
42.0
Prior and concomitant
35
17.5
Unknown
14
7.0
Endocrine therapy
98
49.0
Antiangiogenic drugs
38
19.0
Dental history
Extraction
94
47.0
Denture
20
10.0
Parodontopathy
7
3.5
Implant
2
1.0
No risk factors reported
62
31.0
Unknown/unavailable
15
7.5
Treatment of ONJ
Nonsurgical
79
39.5
Curettage only
92
46.0
Major surgical
15
7.5
Unknown/unavailable
14
7.0
Outcome (3–6 months after ONJ diagnosis and first treatment)
